201 related articles for article (PubMed ID: 29340055)
1. Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.
Liu Y; Deng L; Zhou X; Gong Y; Xu Y; Zhou L; Wan J; Zou B; Wang Y; Zhu J; Ding Z; Peng F; Huang M; Ren L; Lautenschlaeger T; Kong FS; Lu Y
Oncotarget; 2017 Dec; 8(67):111309-111317. PubMed ID: 29340055
[TBL] [Abstract][Full Text] [Related]
2. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
4. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
6. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced
He ZY; Li MF; Lin JH; Lin D; Lin RJ
Cancer Manag Res; 2019; 11():2129-2138. PubMed ID: 30936745
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
Chen Y; Wei J; Cai J; Liu A
BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.
Wang C; Lu X; Zhou Z; Wang J; Hui Z; Liang J; Feng Q; Chen D; Xiao Z; Lv J; Wang X; Wang X; Zhang T; Deng L; Wang W; Xiao J; Li J; Bi N; Wang L
J Cancer; 2019; 10(9):1985-1990. PubMed ID: 31205558
[No Abstract] [Full Text] [Related]
9. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
Wang C; Lu X; Lyu Z; Bi N; Wang L
Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
Wang W; Song Z; Zhang Y
Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing of hypofractionated stereotactic radiotherapy for epidermal growth factor receptor-mutated non-small-cell lung cancer patients with brain metastases.
Liang S; Liu X; Liu J; Na F; Lai J; Du L; Gong Y; Zhu J; Huang M; Zhou X; Xu Y; Zhou L
Asia Pac J Clin Oncol; 2023 Dec; 19(6):731-738. PubMed ID: 37088960
[TBL] [Abstract][Full Text] [Related]
12. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
Front Oncol; 2018; 8():603. PubMed ID: 30619745
[No Abstract] [Full Text] [Related]
13. Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study.
An N; Wang H; Li J; Zhai X; Jing W; Jia W; Kong L; Zhu H; Yu J
Onco Targets Ther; 2019; 12():8311-8318. PubMed ID: 31632080
[TBL] [Abstract][Full Text] [Related]
14. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
15. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.
Sung S; Lee SW; Kwak YK; Kang JH; Hong SH; Kim YS
J Neurooncol; 2018 Aug; 139(1):205-213. PubMed ID: 29644484
[TBL] [Abstract][Full Text] [Related]
16. Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Li C; Guo J; Zhao L; Hu F; Nie W; Wang H; Zheng X; Shen Y; Gu P; Zhang Y; Zhang X
Cancer Manag Res; 2019; 11():3433-3443. PubMed ID: 31114377
[No Abstract] [Full Text] [Related]
17. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.
Dong K; Liang W; Zhao S; Guo M; He Q; Li C; Song H; He J; Xia X
Transl Lung Cancer Res; 2019 Jun; 8(3):268-279. PubMed ID: 31367540
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
19. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases.
Chiou GY; Chiang CL; Yang HC; Shen CI; Wu HM; Chen YW; Chen CJ; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
J Neurosurg; 2022 Aug; 137(2):563-570. PubMed ID: 34920439
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
